Blog
Featured post
Leading US health systems launch the Truveta Genome Project
The Truveta Genome Project creates the world’s largest and most diverse database to discover the science of humanity.
Real-time monitoring of GLP-1 RA medications: Prescription trends from January 2018 through December 2023
Overall prescribing rates (GLP-1 RA prescriptions per total prescriptions) have remained stable in the last 3 months, with rates in December 2023 about the same as rates in...
Truveta awarded real-world data contract by the CDC to study COVID, maternal health, and pediatric care
Truveta, a growing collective of 30 health systems with a shared mission of Saving Lives with Data, was awarded a contract with the U.S. Centers for Disease Control and...
Crohn’s disease and the power of complete, timely, and clean EHR data
Crohn’s disease, a complex chronic inflammatory disorder of the GI tract, affects approximately 780,000 Americans with an estimated 33,000 new cases diagnosed each year. Crohn’s,...
Truveta enhances analytics to accelerate scientifically rigorous clinical research
The pace of new therapy adoption has been limited by the ability to produce data that the medical community trusts. Clinical researchers have historically had difficulty...
Understanding the potential relationship between mental health and cannabis use
There is a complex relationship between cannabis use and mental health. We studied recent time trends of the rate of cannabis-induced disorder emergency department visits and...
10 Truveta Research insights & publications of 2023
As 2023 draws to a close and we reflect on a busy and exciting year for Truveta, something that stands out is the breadth and depth of research Truveta Research has been able to...
First real-world comparative effectiveness study finds tirzepatide (Mounjaro) up to three times more effective than semaglutide (Ozempic) for weight loss
Today Truveta announced new comparative effectiveness research exploring weight loss among patients taking semaglutide (Ozempic) and tirzepatide (Mounjaro). Glucagon-like peptide...
Beyond claims data: Truveta showcases potential of EHR data at ISPOR EU 2023
ISPOR Europe 2023 provided Truveta an opportunity to showcase research findings, interact with life sciences leaders from across the globe, and gain insight into how different...
Reflections from the inaugural Truveta Symposium
Eight months ago, we had a fateful meeting… “We have some incredibly diverse and engaged customers doing innovative work that would benefit from meeting and learning from each...